2.0
25. Okt. 2010
Ehemaliger Mitarbeiter
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Great benefits, wealth of tools and training to do your job, reasonably stable company
Kontras
Company stability in question with patent expiration and Roche take over. Even before this, advancement, outside of core biotech, correlated only with connections or whether you represented a desired demographic niche. Now, that's doubly true.